Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

The Watchlist by The Market Herald Releases New Interviews with NurExone Biologic and SuperBuzz Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / September 13, 2023 / The Watchlist by The Market Herald has announced the release of new interviews with NurExone Biologic and SuperBuzz discussing their latest news.

The Watchlist by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug

NurExone Biologic Inc. (TSXV:NRX) (FSE:J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, has announced that the Company has completed a Pre-Investigational New Drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone's first ExoTherapy product, after receiving a written response from the FDA on August 29, 2023.

For the full interview with CEO Lior Shaltiel and to learn more about NurExone Biologic's news, click here.

SuperBuzz - The Leader in AI Marketing Technology, Partners with Leading Marketing Agency to Ignite Online Sales

SuperBuzz Inc. (TSXV:SPZ) SuperBuzz, a renowned name in the industry, is thrilled to announce a game-changing collaboration with a top-tier marketing agency to accelerate its online marketing and sales initiatives. This strategic partnership aims to bolster SuperBuzz's presence in the digital marketplace, drive brand recognition, and ultimately boost sales to new heights.

For the full interview with CEO Liran Brenner and to learn more about SuperBuzz's news, click here.

Interviews for The Watchlist by The Market Herald are released daily. To learn more about the companies featured in The Watchlist or to explore our other interviews visit The Watchlist by The Market Herald.

About The Market Herald

The Market Herald Canada is the leading source of authoritative breaking stock market news for self-directed investors. Our team of Canadian markets reporters, editors and technologists covers the entire listed company universe in Canada. We cover over 3,985 businesses, their people, their investors, and their customers. We write the stories that move the Canadian capital markets.

DISCLAIMER: Report Card Canada Media Ltd. ("Report Card") is a wholly-owned subsidiary of Market Herald Limited, an Australian company ("Market Herald"). Report Card is not an advisory service, and does not offer, buy, sell, or provide any other rating, analysis or opinion on the securities we discuss. We are retained and compensated by the companies that we provide information on to assist them with making information available to the public. All information available on themarketherald.ca and/or this press release should be considered as commercial advertisement and not an endorsement, offer or recommendation to buy or sell securities. Report Card is not registered with any financial or securities regulatory authority in any province or territory of Canada, will not be performing any registerable activity as defined by the applicable regulatory bodies and do not provide nor claim to provide investment advice or recommendations to any visitor of this site or readers of any content on or originating from themarketherald.ca. Market Herald and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Market Herald's affiliates. In such instances, Market Herald and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Market Herald and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize any conflict. All the information on this document and/or the website - themarketherald.ca - is published in good faith and for general information purpose only. Report Card does not make any warranties about the completeness, reliability, and accuracy of this information. Any action you take upon the information you find on this document and/or website (themarketherald.ca) is strictly at your own risk. Report Card will not be liable for any losses and/or damages in connection with the use of our website. From our website, you can visit other websites by following hyperlinks to such external sites. While we strive to provide only quality links to useful and ethical websites, we have no control over the content and nature of these sites. These links to other websites do not imply a recommendation for all the content found on these sites. Site owners and content may change without notice and may occur before we have the opportunity to remove a link which may have gone 'bad'. Please be also aware that when you leave our website, other sites may have different privacy policies and terms which are beyond our control. Please be sure to check the Privacy Policies of these sites as well as their "Terms of Service" before engaging in any business or uploading any information.

CONTACT:

The Market Herald
marketing@themarketherald.ca
themarketherald.ca

SOURCE: The Market Herald



View source version on accesswire.com:
https://www.accesswire.com/783847/the-watchlist-by-the-market-herald-releases-new-interviews-with-nurexone-biologic-and-superbuzz-discussing-their-latest-news

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.